NodThera is developing a portfolio of novel, potent and selective NLRP3 inflammasome inhibitors, with one clinical-stage candidate and several others in preclinical development. The company is seeking partners to advance its programs through clinical development in a range of indications.
The Immunotherapy has over 1.6K+ startups that comprise of companies developing immunotherapy to treat diseases in humans. This includes companies developing antibodies, vaccines, cytokines, small molecules based immunotherapy for the treatment of various diseases.
There are some things we are better off without. Our lungs would be happier if never exposed to cigarette smoke. Our livers would be healthier if never stuffed with fat. Our arteries would be content without being clogged with cholesterol. And, some scientists argue, our brains would stay sharper without the amyloid-β plaques and tau tangles that accumulate in old age. All these things, and more, have one thing in common: they incite inflammation in our bodies. And they do so by activating a hypersensitive protein called NLRP3.
You bump your elbow, it swells and gets red, then it hurts. Your body dispatches white blood cells to release chemicals that promote wound healing and protect against infection. These are signs of inflammation, the body’s defense against outside dangers.
NLRP3 early and often
Inflammasome inhibitors could offer a step change for a slew of inflammatory diseases and pharma is taking notice. Two acquisitions in six months show the first inflammasome target — NLRP3 — is gaining momentum, but the question is how fast drug developers can discern the best set of indications from the sea of possibilities.
Q. What is the appeal of working with a small biotech following a career in big pharma?
Working in Pharma provided me with a wealth of opportunities to learn our industry, both from an R&D perspective but also through a commercial, executive management and strategy lens. Leading Business Development activities at J&J, and then more recently at Sanofi Genzyme, allowed me to interact and learn from multiple functions across the value chain from drug discovery, IP and manufacturing to translational medicine, clinical development and regulatory. I have had the opportunity to work with some great teams with deep expertise and benefited from the diversity of those experiences. I now welcome the opportunity to apply those learnings to driving projects in a nimble, agile biotech company.